Philip Reigan
Concepts (395)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ribosomal Protein S6 Kinases, 90-kDa | 5 | 2025 | 14 | 2.900 |
Why?
| | Protein Kinase Inhibitors | 10 | 2025 | 916 | 2.510 |
Why?
| | Thymidine Phosphorylase | 7 | 2022 | 14 | 2.340 |
Why?
| | Antineoplastic Agents | 17 | 2025 | 2129 | 2.330 |
Why?
| | Pyrimidines | 6 | 2021 | 470 | 1.670 |
Why?
| | Protein-Tyrosine Kinases | 6 | 2019 | 434 | 1.540 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2025 | 197 | 1.410 |
Why?
| | Cell Cycle Proteins | 5 | 2018 | 611 | 1.360 |
Why?
| | Nuclear Proteins | 6 | 2018 | 710 | 1.350 |
Why?
| | Enzyme Inhibitors | 9 | 2021 | 838 | 1.210 |
Why?
| | Neoplasms | 6 | 2025 | 2644 | 1.200 |
Why?
| | Models, Molecular | 26 | 2025 | 1591 | 1.090 |
Why?
| | STAT3 Transcription Factor | 3 | 2022 | 205 | 1.060 |
Why?
| | Glioblastoma | 3 | 2022 | 343 | 1.030 |
Why?
| | Pyrazoles | 4 | 2018 | 423 | 0.940 |
Why?
| | Pyrroles | 2 | 2021 | 211 | 0.870 |
Why?
| | Small Molecule Libraries | 3 | 2025 | 95 | 0.830 |
Why?
| | Prodrugs | 4 | 2007 | 49 | 0.780 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 800 | 0.750 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 8 | 2011 | 32 | 0.730 |
Why?
| | Pyrimidinones | 4 | 2018 | 113 | 0.720 |
Why?
| | Protein Isoforms | 2 | 2025 | 400 | 0.690 |
Why?
| | Purines | 1 | 2021 | 176 | 0.660 |
Why?
| | Pteridines | 1 | 2020 | 20 | 0.650 |
Why?
| | Cell Survival | 8 | 2022 | 1117 | 0.630 |
Why?
| | Structure-Activity Relationship | 10 | 2020 | 573 | 0.620 |
Why?
| | Indolequinones | 5 | 2011 | 5 | 0.600 |
Why?
| | Aldehydes | 8 | 2014 | 144 | 0.560 |
Why?
| | HSP90 Heat-Shock Proteins | 5 | 2011 | 46 | 0.560 |
Why?
| | Protein Binding | 12 | 2021 | 2223 | 0.520 |
Why?
| | Medulloblastoma | 2 | 2016 | 196 | 0.510 |
Why?
| | Glutamate-Cysteine Ligase | 2 | 2013 | 20 | 0.510 |
Why?
| | Brain Neoplasms | 3 | 2020 | 1241 | 0.500 |
Why?
| | Xanthine Oxidase | 2 | 2007 | 81 | 0.490 |
Why?
| | Benzoquinones | 4 | 2011 | 48 | 0.480 |
Why?
| | Cell Line, Tumor | 18 | 2022 | 3399 | 0.480 |
Why?
| | Uracil | 3 | 2021 | 31 | 0.470 |
Why?
| | Isoxazoles | 5 | 2023 | 54 | 0.450 |
Why?
| | Molecular Dynamics Simulation | 4 | 2025 | 238 | 0.430 |
Why?
| | Hydroquinones | 3 | 2011 | 29 | 0.430 |
Why?
| | Cisplatin | 1 | 2016 | 318 | 0.430 |
Why?
| | Lactams, Macrocyclic | 3 | 2011 | 49 | 0.420 |
Why?
| | Deoxyribose | 1 | 2013 | 6 | 0.420 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2020 | 193 | 0.400 |
Why?
| | Glutathione | 2 | 2011 | 357 | 0.390 |
Why?
| | Humans | 59 | 2025 | 136783 | 0.380 |
Why?
| | Molecular Structure | 5 | 2020 | 495 | 0.350 |
Why?
| | Molecular Docking Simulation | 6 | 2023 | 112 | 0.340 |
Why?
| | Catalytic Domain | 5 | 2021 | 226 | 0.310 |
Why?
| | Protein Conformation | 4 | 2021 | 940 | 0.310 |
Why?
| | Cell Line | 5 | 2022 | 2836 | 0.310 |
Why?
| | Glucose | 2 | 2013 | 1019 | 0.300 |
Why?
| | Cell Proliferation | 10 | 2020 | 2473 | 0.300 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2014 | 100 | 0.300 |
Why?
| | Imidazoles | 3 | 2021 | 239 | 0.300 |
Why?
| | Molecular Targeted Therapy | 3 | 2016 | 413 | 0.290 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2021 | 226 | 0.280 |
Why?
| | Amides | 2 | 2020 | 93 | 0.280 |
Why?
| | Growth Inhibitors | 1 | 2007 | 43 | 0.270 |
Why?
| | Animals | 29 | 2025 | 36768 | 0.270 |
Why?
| | Signal Transduction | 6 | 2022 | 5065 | 0.270 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2013 | 436 | 0.260 |
Why?
| | src Homology Domains | 2 | 2016 | 41 | 0.250 |
Why?
| | Thyroid Neoplasms | 2 | 2021 | 337 | 0.240 |
Why?
| | Pancreatic Neoplasms | 4 | 2009 | 931 | 0.240 |
Why?
| | Binding Sites | 6 | 2018 | 1308 | 0.230 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 530 | 0.230 |
Why?
| | Rotenone | 1 | 2024 | 11 | 0.230 |
Why?
| | G-Quadruplexes | 2 | 2022 | 19 | 0.220 |
Why?
| | Pyrrolidines | 1 | 2004 | 80 | 0.220 |
Why?
| | alpha-Synuclein | 1 | 2024 | 34 | 0.220 |
Why?
| | Giardia lamblia | 1 | 2024 | 22 | 0.210 |
Why?
| | Dopaminergic Neurons | 1 | 2024 | 64 | 0.210 |
Why?
| | Thymidine | 2 | 2022 | 60 | 0.210 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 132 | 0.200 |
Why?
| | Rifabutin | 3 | 2008 | 6 | 0.200 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2023 | 50 | 0.200 |
Why?
| | Receptors, Glucocorticoid | 1 | 2024 | 155 | 0.200 |
Why?
| | DNA | 3 | 2016 | 1458 | 0.200 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2014 | 93 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 671 | 0.190 |
Why?
| | Ear Diseases | 1 | 2022 | 15 | 0.190 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.190 |
Why?
| | K562 Cells | 2 | 2020 | 89 | 0.190 |
Why?
| | Virus Internalization | 1 | 2022 | 47 | 0.190 |
Why?
| | Models, Chemical | 1 | 2023 | 268 | 0.190 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 48 | 0.190 |
Why?
| | Catalysis | 3 | 2013 | 316 | 0.180 |
Why?
| | Drug Synergism | 3 | 2021 | 378 | 0.180 |
Why?
| | Quinone Reductases | 2 | 2011 | 17 | 0.180 |
Why?
| | Fluorouracil | 1 | 2022 | 210 | 0.180 |
Why?
| | Maneb | 1 | 2020 | 9 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2022 | 139 | 0.170 |
Why?
| | Receptors, Androgen | 1 | 2022 | 149 | 0.170 |
Why?
| | Heterocyclic Compounds | 1 | 2020 | 20 | 0.170 |
Why?
| | Mice | 18 | 2024 | 17731 | 0.170 |
Why?
| | Lipoprotein Lipase | 1 | 2020 | 59 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 152 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2045 | 0.170 |
Why?
| | Fluorescence | 1 | 2020 | 159 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 185 | 0.170 |
Why?
| | Neovascularization, Pathologic | 1 | 2022 | 301 | 0.170 |
Why?
| | Polymorphism, Genetic | 2 | 2014 | 657 | 0.160 |
Why?
| | Amino Acid Sequence | 8 | 2014 | 2145 | 0.150 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 36 | 0.150 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 5744 | 0.150 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2019 | 34 | 0.150 |
Why?
| | Protein Carbonylation | 3 | 2013 | 54 | 0.150 |
Why?
| | Enzyme Assays | 1 | 2018 | 25 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2013 | 591 | 0.150 |
Why?
| | Pyridazines | 1 | 2018 | 56 | 0.140 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2018 | 40 | 0.140 |
Why?
| | Phosphorylation | 3 | 2018 | 1756 | 0.140 |
Why?
| | Escherichia coli | 4 | 2006 | 812 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2022 | 397 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 267 | 0.140 |
Why?
| | Dihydropyridines | 1 | 2017 | 15 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 596 | 0.140 |
Why?
| | Cyclic S-Oxides | 1 | 2016 | 1 | 0.130 |
Why?
| | Niclosamide | 1 | 2016 | 2 | 0.130 |
Why?
| | Glycoproteins | 2 | 2011 | 344 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2022 | 619 | 0.130 |
Why?
| | Fluorescence Polarization | 1 | 2016 | 37 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 214 | 0.130 |
Why?
| | Antigens, Neoplasm | 2 | 2011 | 320 | 0.130 |
Why?
| | Lysine | 2 | 2023 | 293 | 0.130 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 44 | 0.130 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.130 |
Why?
| | Antioxidants | 2 | 2011 | 578 | 0.130 |
Why?
| | MicroRNAs | 1 | 2023 | 697 | 0.130 |
Why?
| | Molecular Sequence Data | 7 | 2014 | 2903 | 0.130 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2013 | 144 | 0.120 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 19 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2022 | 736 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2022 | 826 | 0.120 |
Why?
| | Crystallography, X-Ray | 5 | 2017 | 485 | 0.120 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 12 | 0.120 |
Why?
| | Drug Design | 1 | 2016 | 166 | 0.120 |
Why?
| | Cells, Cultured | 3 | 2020 | 4194 | 0.120 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1062 | 0.120 |
Why?
| | Retinaldehyde | 1 | 2014 | 4 | 0.120 |
Why?
| | Allosteric Regulation | 3 | 2023 | 97 | 0.120 |
Why?
| | Acetaldehyde | 1 | 2014 | 17 | 0.120 |
Why?
| | HeLa Cells | 1 | 2016 | 636 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2020 | 491 | 0.110 |
Why?
| | Drug Discovery | 1 | 2016 | 141 | 0.110 |
Why?
| | Sulfhydryl Compounds | 2 | 2020 | 191 | 0.110 |
Why?
| | Recombinant Proteins | 5 | 2011 | 1354 | 0.110 |
Why?
| | Mass Spectrometry | 4 | 2012 | 739 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2020 | 557 | 0.110 |
Why?
| | Membrane Proteins | 2 | 2011 | 1162 | 0.110 |
Why?
| | DNA Repair | 1 | 2016 | 230 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 849 | 0.110 |
Why?
| | Computer Simulation | 4 | 2014 | 973 | 0.110 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 190 | 0.110 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2014 | 108 | 0.110 |
Why?
| | Fatty Liver, Alcoholic | 1 | 2013 | 15 | 0.100 |
Why?
| | Heat-Shock Proteins | 1 | 2014 | 142 | 0.100 |
Why?
| | Protein Folding | 2 | 2014 | 281 | 0.100 |
Why?
| | Mammary Glands, Animal | 2 | 2011 | 129 | 0.100 |
Why?
| | Adenosine Triphosphatases | 1 | 2014 | 165 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 94 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.100 |
Why?
| | Lactation | 2 | 2011 | 181 | 0.100 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2014 | 171 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 345 | 0.100 |
Why?
| | Cell Cycle | 2 | 2014 | 601 | 0.100 |
Why?
| | Inflammation | 2 | 2022 | 2834 | 0.100 |
Why?
| | Gout | 1 | 2013 | 36 | 0.100 |
Why?
| | Gene Expression Regulation | 3 | 2013 | 2603 | 0.100 |
Why?
| | Electron Transport Complex I | 1 | 2012 | 41 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 162 | 0.090 |
Why?
| | Acridines | 1 | 2011 | 7 | 0.090 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2012 | 70 | 0.090 |
Why?
| | Glutathione Reductase | 1 | 2011 | 25 | 0.090 |
Why?
| | Status Epilepticus | 1 | 2012 | 50 | 0.090 |
Why?
| | Glutathione Peroxidase | 1 | 2011 | 43 | 0.090 |
Why?
| | Apoptosis | 6 | 2021 | 2548 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1683 | 0.090 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2011 | 45 | 0.090 |
Why?
| | Glutathione Transferase | 1 | 2011 | 104 | 0.090 |
Why?
| | Flavoproteins | 1 | 2011 | 8 | 0.090 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 219 | 0.090 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 455 | 0.090 |
Why?
| | Glycolipids | 1 | 2011 | 42 | 0.090 |
Why?
| | Mitochondria, Liver | 1 | 2011 | 73 | 0.090 |
Why?
| | Transcriptional Activation | 1 | 2013 | 378 | 0.090 |
Why?
| | Organelles | 1 | 2011 | 58 | 0.090 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 528 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 2012 | 320 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 864 | 0.080 |
Why?
| | Sirtuin 3 | 1 | 2011 | 61 | 0.080 |
Why?
| | Milk | 1 | 2011 | 124 | 0.080 |
Why?
| | Enzyme Activation | 2 | 2013 | 813 | 0.080 |
Why?
| | Brain | 2 | 2012 | 2669 | 0.080 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 346 | 0.080 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2011 | 137 | 0.080 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 467 | 0.080 |
Why?
| | Kinetics | 1 | 2013 | 1668 | 0.080 |
Why?
| | Indoles | 2 | 2015 | 410 | 0.080 |
Why?
| | Cell Movement | 1 | 2014 | 969 | 0.080 |
Why?
| | Phospholipids | 1 | 2011 | 222 | 0.080 |
Why?
| | Thioredoxin-Disulfide Reductase | 1 | 2009 | 13 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2020 | 2239 | 0.080 |
Why?
| | Oxidative Stress | 2 | 2014 | 1309 | 0.080 |
Why?
| | Adenosine Triphosphate | 1 | 2011 | 486 | 0.080 |
Why?
| | Peroxiredoxin VI | 1 | 2008 | 5 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2022 | 953 | 0.080 |
Why?
| | Protein Structure, Tertiary | 4 | 2014 | 867 | 0.080 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2012 | 360 | 0.070 |
Why?
| | Down-Regulation | 1 | 2011 | 657 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2024 | 4279 | 0.070 |
Why?
| | Protein Interaction Domains and Motifs | 3 | 2013 | 151 | 0.070 |
Why?
| | Cross-Linking Reagents | 1 | 2008 | 212 | 0.070 |
Why?
| | Quinones | 1 | 2007 | 9 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 512 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2013 | 1500 | 0.070 |
Why?
| | Spectrophotometry, Infrared | 1 | 2007 | 54 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 26 | 0.070 |
Why?
| | Mutation | 4 | 2021 | 3953 | 0.070 |
Why?
| | Cell Membrane | 1 | 2011 | 736 | 0.070 |
Why?
| | Galactosides | 1 | 2006 | 5 | 0.070 |
Why?
| | beta-Galactosidase | 1 | 2006 | 77 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2012 | 918 | 0.060 |
Why?
| | Substrate Specificity | 3 | 2014 | 384 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1799 | 0.060 |
Why?
| | Arginine | 3 | 2013 | 271 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2831 | 0.060 |
Why?
| | Nitroimidazoles | 1 | 2005 | 9 | 0.060 |
Why?
| | Carcinoma | 1 | 2007 | 236 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 3 | 2011 | 180 | 0.060 |
Why?
| | Biological Availability | 1 | 2005 | 147 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2007 | 616 | 0.060 |
Why?
| | Phenanthrenes | 1 | 2024 | 13 | 0.060 |
Why?
| | Emetine | 1 | 2024 | 6 | 0.050 |
Why?
| | Parkinsonian Disorders | 1 | 2024 | 35 | 0.050 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 2 | 2014 | 23 | 0.050 |
Why?
| | Substantia Nigra | 1 | 2024 | 57 | 0.050 |
Why?
| | Computational Biology | 1 | 2008 | 645 | 0.050 |
Why?
| | Mice, Nude | 2 | 2021 | 692 | 0.050 |
Why?
| | Polycomb-Group Proteins | 1 | 2023 | 28 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2024 | 188 | 0.050 |
Why?
| | Benzamides | 1 | 2023 | 217 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2011 | 1201 | 0.050 |
Why?
| | Exoribonucleases | 1 | 2023 | 49 | 0.050 |
Why?
| | Ribosomes | 1 | 2024 | 185 | 0.050 |
Why?
| | Peptides | 2 | 2023 | 980 | 0.050 |
Why?
| | Alcohols | 1 | 2022 | 29 | 0.050 |
Why?
| | Molecular Conformation | 2 | 2015 | 150 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2022 | 29 | 0.050 |
Why?
| | Mesocricetus | 1 | 2022 | 39 | 0.050 |
Why?
| | Hep G2 Cells | 2 | 2013 | 65 | 0.050 |
Why?
| | Ear | 1 | 2022 | 31 | 0.050 |
Why?
| | Stress, Physiological | 2 | 2015 | 442 | 0.050 |
Why?
| | Ethanol | 3 | 2012 | 608 | 0.050 |
Why?
| | Peptide Mapping | 2 | 2012 | 64 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 160 | 0.050 |
Why?
| | Sequence Alignment | 2 | 2012 | 345 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 123 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 24 | 0.040 |
Why?
| | Perilipin-2 | 2 | 2011 | 41 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2003 | 226 | 0.040 |
Why?
| | Neural Crest | 1 | 2022 | 116 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 107 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 193 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 69 | 0.040 |
Why?
| | Cell-Free System | 2 | 2011 | 53 | 0.040 |
Why?
| | Blotting, Western | 2 | 2013 | 1225 | 0.040 |
Why?
| | Viral Load | 1 | 2022 | 460 | 0.040 |
Why?
| | HEK293 Cells | 2 | 2013 | 728 | 0.040 |
Why?
| | Lipoproteins | 1 | 2020 | 167 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1428 | 0.040 |
Why?
| | Carbon | 1 | 2020 | 223 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 321 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2007 | 1998 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 350 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 256 | 0.040 |
Why?
| | Triglycerides | 1 | 2020 | 524 | 0.040 |
Why?
| | Microglia | 1 | 2020 | 251 | 0.040 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 221 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 2 | 2013 | 532 | 0.040 |
Why?
| | Genomics | 2 | 2014 | 790 | 0.040 |
Why?
| | Male | 7 | 2024 | 67361 | 0.030 |
Why?
| | Drug Resistance, Multiple | 1 | 2017 | 25 | 0.030 |
Why?
| | Female | 8 | 2022 | 72840 | 0.030 |
Why?
| | Dimerization | 1 | 2017 | 198 | 0.030 |
Why?
| | Child | 1 | 2016 | 21968 | 0.030 |
Why?
| | Models, Biological | 2 | 2014 | 1769 | 0.030 |
Why?
| | Nitroglycerin | 1 | 2014 | 17 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2012 | 2481 | 0.030 |
Why?
| | Circular Dichroism | 1 | 2015 | 150 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 86 | 0.030 |
Why?
| | Unfolded Protein Response | 1 | 2014 | 58 | 0.030 |
Why?
| | Calorimetry | 1 | 2014 | 69 | 0.030 |
Why?
| | Magnesium | 1 | 2014 | 158 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 387 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3199 | 0.030 |
Why?
| | Adult | 1 | 2016 | 37616 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 98 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 2013 | 39 | 0.030 |
Why?
| | Lung | 2 | 2022 | 4065 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2013 | 76 | 0.030 |
Why?
| | RNA Splice Sites | 1 | 2013 | 45 | 0.030 |
Why?
| | Hyperuricemia | 1 | 2013 | 44 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1541 | 0.020 |
Why?
| | Biotinylation | 1 | 2012 | 32 | 0.020 |
Why?
| | Kainic Acid | 1 | 2012 | 35 | 0.020 |
Why?
| | Synaptosomes | 1 | 2012 | 30 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2012 | 39 | 0.020 |
Why?
| | Anilino Naphthalenesulfonates | 1 | 2012 | 10 | 0.020 |
Why?
| | Anura | 1 | 2012 | 39 | 0.020 |
Why?
| | Electron Transport Complex IV | 1 | 2012 | 59 | 0.020 |
Why?
| | Fishes | 1 | 2013 | 100 | 0.020 |
Why?
| | Methyltransferases | 1 | 2013 | 78 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2012 | 49 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 114 | 0.020 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2013 | 137 | 0.020 |
Why?
| | Molecular Weight | 1 | 2012 | 334 | 0.020 |
Why?
| | Ubiquitination | 1 | 2012 | 102 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Sulfonamides | 1 | 2015 | 512 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 115 | 0.020 |
Why?
| | Rats | 2 | 2012 | 5628 | 0.020 |
Why?
| | Telomere | 1 | 2015 | 280 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 264 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 90 | 0.020 |
Why?
| | Amination | 1 | 2011 | 2 | 0.020 |
Why?
| | Oxidants | 1 | 2012 | 110 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 340 | 0.020 |
Why?
| | Alkylation | 1 | 2011 | 26 | 0.020 |
Why?
| | Nucleic Acid Conformation | 1 | 2015 | 729 | 0.020 |
Why?
| | Genome, Human | 1 | 2014 | 424 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 231 | 0.020 |
Why?
| | Protein Subunits | 1 | 2012 | 239 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1731 | 0.020 |
Why?
| | Lipid Droplets | 1 | 2011 | 23 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 432 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2011 | 202 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2013 | 210 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 513 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2012 | 534 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 182 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2011 | 72 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2011 | 82 | 0.020 |
Why?
| | Membranes, Artificial | 1 | 2011 | 72 | 0.020 |
Why?
| | Mammary Glands, Human | 1 | 2011 | 64 | 0.020 |
Why?
| | Lipid Peroxidation | 1 | 2011 | 152 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 664 | 0.020 |
Why?
| | NAD | 1 | 2011 | 77 | 0.020 |
Why?
| | Mammals | 1 | 2012 | 283 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 248 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 973 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 365 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2011 | 376 | 0.020 |
Why?
| | Transfection | 1 | 2012 | 945 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1089 | 0.020 |
Why?
| | DNA Breaks, Single-Stranded | 1 | 2009 | 5 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1318 | 0.020 |
Why?
| | Phylogeny | 1 | 2012 | 896 | 0.020 |
Why?
| | Animal Feed | 1 | 2008 | 53 | 0.020 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 2008 | 11 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2012 | 488 | 0.020 |
Why?
| | Hypoxia | 1 | 2015 | 1107 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 2008 | 86 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1250 | 0.020 |
Why?
| | Caspases | 1 | 2009 | 247 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1396 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 933 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2006 | 17 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 92 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 95 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2006 | 106 | 0.020 |
Why?
| | Deoxyuridine | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Respiration | 1 | 2006 | 102 | 0.020 |
Why?
| | Thiazoles | 1 | 2006 | 123 | 0.020 |
Why?
| | Smoke | 1 | 2007 | 144 | 0.020 |
Why?
| | Cysteine | 1 | 2007 | 205 | 0.020 |
Why?
| | Mitochondria | 1 | 2012 | 946 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2012 | 784 | 0.020 |
Why?
| | Superoxides | 1 | 2006 | 202 | 0.020 |
Why?
| | Drug Carriers | 1 | 2006 | 127 | 0.020 |
Why?
| | Proteomics | 1 | 2012 | 1108 | 0.010 |
Why?
| | Drug Interactions | 1 | 2006 | 405 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2006 | 256 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2006 | 362 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2006 | 696 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 396 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 6792 | 0.010 |
Why?
| | Liver | 1 | 2008 | 1938 | 0.010 |
Why?
| | Aged | 1 | 2019 | 23729 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 11069 | 0.010 |
Why?
| | Cytokines | 1 | 2007 | 2088 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 33200 | 0.010 |
Why?
|
|
Reigan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|